鈣調(diào)磷酸酶抑制劑（CNI）是實(shí)體器官移植和造血干細(xì)胞移植術(shù)后的主要免疫抑制藥物。盡管CNI極大的改善了移植患者預(yù)后，但該類藥物引起的不良反應(yīng)也經(jīng)常發(fā)生。CNI所致的疼痛綜合征（CIPS）是一種罕見(jiàn)的、嚴(yán)重的不良反應(yīng)，其發(fā)生與鈣調(diào)磷酸酶生理功能的中斷有關(guān)?；颊叱１憩F(xiàn)為雙下肢疼痛，嚴(yán)重影響患者運(yùn)動(dòng)能力和生活質(zhì)量，因此，主要對(duì)CIPS的流行病學(xué)、臨床表現(xiàn)、實(shí)驗(yàn)室檢查、影像學(xué)表現(xiàn)、診斷、發(fā)病機(jī)制及治療選擇進(jìn)行綜述，以期為臨床提供參考。

Calcineurin inhibitors (CNI) are the mainstay immunosuppressive drugs for solid organ transplantation and hematopoietic stem cell transplantation. Although CNI excellently improve patient outcomes, adverse effects are frequently encountered. Calcineurin inhibitor-induced pain syndrome (CIPS) is a rare and severe adverse effect of CNI, which appears to be due to the interruption of the physiologic function of calcineurin. Patients with CIPS diagnosis involve pain in the lower extremities. CIPS seriously affects the activities of daily living and life quality of the patients. Therefore, the epidemiology, clinical manifestation, laboratory examination, imaging manifestations, diagnosis, pathogenesis, and treatment choices are reviewed in this paper, in order to provide references for clinical practice.

R977

國(guó)家自然科學(xué)基金資助項(xiàng)目（81503127）